Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine
July 15, 2021 Vol. 385 No. 3
http://www.nejm.org/toc/nejm/medical-journal

 

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents R.W. Frenck, Jr., and Others
Conclusions
The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19. (Funded by BioNTech and Pfizer; C4591001 ClinicalTrials.gov number, NCT04368728. opens in new tab.)